ACAD supply chain intelligence for ACADIA Pharmaceuticals Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
ACADIA Pharmaceuticals Inc. (ACAD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NEUREN | NEUREN | 90% | The Company paid Neuren an upfront license fee of $ 10.0 million and it may be required to pay up to an additional $ 455.0 million in milestone payments based on the achievement of certain developmen… |
| SANIONA-A-S | SANIONA-A-S | 90% | The Company paid Saniona an upfront fee of $ 28.0 million and it may be required to pay up to $ 582.0 million in milestone payments based on the achievement of certain development and annual net sale… |
| STOKE-THERAPEUTICS-INC | STOKE-THERAPEUTICS-INC | 90% | The Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first quarter of 2022 as there is no altern… |
| GHRS | GH Research PLC | 72% | Reciprocal relationship from GHRS graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from GHRS graph: 1 million for the year ended December 31, 2024. This movement is primarily a… |
| STOK | Stoke Therapeutics, Inc. | 72% | Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: ort is expected to be completed in the third quarter of 2026. Data from the … |
| MPLT | MapLight Therapeutics, Inc. | 62% | Reciprocal relationship from MPLT graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | 72% | Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD graph: 2023 as there is no alternative use for the asset. In January 2022, the Company entered into a license and collaborat… |
| STOK | Stoke Therapeutics, Inc. | 72% | 2023 as there is no alternative use for the asset. In January 2022, the Company entered into a license and collaboration agreement with Stoke Therapeutics, Inc. (Stoke) to discover, develop and comme… |
| AUPH | Aurinia Pharmaceuticals Inc. | 62% | Reciprocal relationship from AUPH graph: Reciprocal relationship from ACAD graph: . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for a… |
| AUROBINDO-PHARMA-LIMITED | AUROBINDO-PHARMA-LIMITED | 62% | . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q… |
| AUROBINDO-PHARMA-USA-INC | AUROBINDO-PHARMA-USA-INC | 62% | . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q… |
| HETERO-LABS-LIMITED | HETERO-LABS-LIMITED | 62% | . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q… |
| HETERO-USA-INC | HETERO-USA-INC | 62% | . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q… |
| MSN-LABORATORIES-PRIVATE-LTD | MSN-LABORATORIES-PRIVATE-LTD | 62% | . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q… |
| NEUREN-PHARMACEUTICALS-LIMITED | NEUREN-PHARMACEUTICALS-LIMITED | 62% | including third-party manufacturing costs, freight, and indirect overhead costs. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on managemen… |
| TEVA | Teva Pharmaceutical Industries Limited | 62% | Reciprocal relationship from TEVA graph: Reciprocal relationship from ACAD graph: . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for a… |
| TEVA-PHARMACEUTICAL-INDUSTRIES-LTD | TEVA-PHARMACEUTICAL-INDUSTRIES-LTD | 62% | . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q… |
| TEVA-PHARMACEUTICALS-USA-INC | TEVA-PHARMACEUTICALS-USA-INC | 62% | . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first q… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ACAD-DEBT | Debt stack $22,000 | 90% | Market cache reports total debt of $22,000. |
| ACAD-DEBT-7450 | Warrants outstanding: 0.35 | 90% | xbrl warrant detail from xbrl 2012-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ACAD-OWNER-RTW-INVESTMENTS-LP | RTW INVESTMENTS, LP | 95% | 13F/ownership overlay lists RTW INVESTMENTS, LP; shares held 7,144,524; value $159.0B; as of 2026-03-31. |
| ACAD-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 95% | 13F/ownership overlay lists BARCLAYS PLC; shares held 3,315,067; value $66.7B; as of 2026-03-31. |
| ACAD-OWNER-FIRST-TRUST-ADVISORS-LP | FIRST TRUST ADVISORS LP | 95% | 13F/ownership overlay lists FIRST TRUST ADVISORS LP; shares held 3,343,868; value $74.4B; as of 2026-03-31. |
| ACAD-OWNER-BLACKROCK-INC | BlackRock, Inc. | 95% | 13F/ownership overlay lists BlackRock, Inc.; shares held 21,550,921; value $479.7B; as of 2026-03-31. |
| ACAD-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD CAPITAL MANAGEMENT LLC; shares held 11,322,800; value $252.0B; as of 2026-03-31. |
| ACAD-OWNER-STATE-STREET-CORP | STATE STREET CORP | 95% | 13F/ownership overlay lists STATE STREET CORP; shares held 8,332,771; value $185.5B; as of 2026-03-31. |
| ACAD-OWNER-VANGUARD-PORTFOLIO-MANAGEMENT-LLC | VANGUARD PORTFOLIO MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD PORTFOLIO MANAGEMENT LLC; shares held 8,671,645; value $193.0B; as of 2026-03-31. |
| ACAD-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | GEODE CAPITAL MANAGEMENT, LLC | 95% | 13F/ownership overlay lists GEODE CAPITAL MANAGEMENT, LLC; shares held 3,464,689; value $77.1B; as of 2026-03-31. |
| ACAD-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 3,423,531; value $80.2B; as of 2026-03-31. |
| ACAD-OWNER-BAKER-BROS-ADVISORS-LP | BAKER BROS. ADVISORS LP | 95% | 13F/ownership overlay lists BAKER BROS. ADVISORS LP; shares held 42,896,690; ownership 24.90%; value $954.9B; as of 2026-03-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| GHRS | GH Research PLC | 100.00 | 1 | ['supplier'] |
| STOK | Stoke Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| TEVA | Teva Pharmaceutical Industries Limited | 100.00 | 1 | ['customer'] |
| MPLT | MapLight Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| AUPH | Aurinia Pharmaceuticals Inc. | 100.00 | 1 | ['customer'] |
| CRNT | Ceragon Networks Ltd. | 50.00 | 2 | |
| ADCT | ADC Therapeutics SA | 50.00 | 2 | |
| ARDX | Ardelyx, Inc. | 50.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 50.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 50.00 | 2 | |
| HALO | Halozyme Therapeutics, Inc. | 50.00 | 2 | |
| GNMSF | Genmab A/S | 50.00 | 2 | |
| KR | The Kroger Co. | 50.00 | 2 | |
| NBIX | Neurocrine Biosciences, Inc. | 50.00 | 2 | |
| KZR | Kezar Life Sciences, Inc. | 50.00 | 2 | |
| MYGN | Myriad Genetics, Inc. | 50.00 | 2 | |
| NONOF | Novo Nordisk A/S | 50.00 | 2 | |
| MS-PE | Morgan Stanley | 50.00 | 2 | |
| SGMT | Sagimet Biosciences Inc. | 50.00 | 2 | |
| TEVJF | Teva Pharmaceutical Industries Limited | 50.00 | 2 |